Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus

Next Previous
Trial Profile

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 05 May 2022 Results from trials ABES and ABET evaluating Immunogenicity of LY2963016 insulin glargine and Lantus R insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus published in the Diabetes, Obesity and Metabolism
  • 26 Apr 2022 Results (n=210) of post hoc analysis providing the first evidence for switching from IGlar to LY IGlar in Chinese patients with T1DM, published in the Diabetes Therapy
  • 01 Oct 2021 Primary endpoint (Change from Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus) has been met according to the results published in the Diabetes, Obesity and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top